Precision BioSciences Posts Strong 2025, Advances Gene Editing Pipeline
Event summary
- Precision BioSciences reported $34.2 million in revenue for Q4 2025, up from $0.6 million in the same period of 2024, driven by revenue recognition from Novartis and Imugene.
- The company extended its cash runway through 2028, supported by a $75 million financing round in November 2025.
- Clinical data for PBGENE-HBV, the company’s Hepatitis B program, showed dose-dependent antiviral activity and molecular evidence of viral DNA gene editing.
- Precision BioSciences received IND clearance for PBGENE-DMD (Duchenne muscular dystrophy) in February 2026, paving the way for clinical trial initiation.
The big picture
Precision BioSciences' 2025 results highlight the increasing momentum behind in vivo gene editing, a field attracting significant investment and showing early clinical promise. While the company's revenue is still relatively small, the progress on PBGENE-HBV and PBGENE-DMD positions it as a key player in the race to develop curative therapies for genetic diseases. The extended cash runway provides breathing room, but continued clinical success and strategic partnerships will be essential for long-term value creation.
What we're watching
- Clinical Efficacy
- The ongoing ELIMINATE-B trial will be critical to determine if PBGENE-HBV can achieve a functional cure for Hepatitis B, and whether the observed molecular evidence translates to sustained viral suppression.
- Regulatory Pathway
- The FDA's feedback on the PBGENE-DMD program and the potential for a Priority Review Voucher will significantly impact the program's timeline and commercial prospects.
- Partner Synergies
- The continued collaboration with Novartis, beyond hemoglobinopathies, will reveal the breadth of Precision’s ARCUS platform and potential for future revenue streams.
Related topics